Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406323 | 0.94 | CA12 (0.41) | CA12CA1CA9STAT3GAA | |
| SCHEMBL14997971 | 0.91 | CA1 (0.44) | CA12CA1CA9STAT3GAA | |
| SCHEMBL11138066 | 0.88 | CA12 (0.42) | CA12CA1CA9STAT3GAA | |
| SCHEMBL14997649 | 0.85 | CA12 (0.40) | CA12CA1CA9STAT3GAA | |
| SCHEMBL2848424 | 0.85 | CA12 (0.40) | CA12CA1CA9STAT3GAA | |
| SCHEMBL9672034 | 0.84 | CA12 (0.47) | CA12CA1CA9STAT3GAA | |
| SCHEMBL4801283 | 0.83 | CYP1A2 (0.44) | CA12CA1CA9STAT3GAA | |
| SCHEMBL23038759 | 0.83 | CA9 (0.39) | CA12CA1CA9STAT3GAA | |
| SCHEMBL3346514 | 0.83 | CA12 (0.41) | CA12CA1CA9STAT3GAA | |
| SCHEMBL2841787 | 0.83 | MCHR1 (0.39) | CA12CA1CA9STAT3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805416-A | Preparation method of propargyl alpha-amido borate compound | 中山大学 | 2022-07-29 | — | — | CN | disclosed |
| EP-3194418-B1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-113582988-A | Pyridinocyclic compound and medical application thereof | 正大天晴药业集团股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20180334436-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
| EP-3383866-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | ViiV Healthcare UK Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| EP-2968576-B1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | THE FLORIDA STATE UNIV RESEARCH FOUNDATION INCORPORATED (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3194418-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | Prevacus Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017093938-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-20160168188-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160168188-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20140275572-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275572-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275572-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | PREVACUS INC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2013-06-06 | — | — | US | disclosed |
| EP-0659735-B1 | PROCESS FOR PRODUCING ANILINE DERIVATIVE | SAGAMI CHEM RES (JP) | 1999-01-13 | — | — | EP | disclosed |
| US-5639915-A | Process for the production of aniline derivatives | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0659735-A1 | PROCESS FOR PRODUCING ANILINE DERIVATIVE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-4708963-A | Novel carbacyclins, their preparation and use | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-11-24 | — | — | US | disclosed |
| US-4423067-A | Carbacyclins, their preparation and use | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-12-27 | — | — | US | disclosed |
| US-4014919-A | Process for preparing methyl jasmonate and related compounds | THE DOW CHEMICAL COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | MSH6, AP3M1, PMS2 | CA12 553/4885CA1 3099/4885CA9 1398/4885 |
| US-20180334436-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | MAVS, EIF2AK2, SARS1 | CA12 3567/4885CA1 3074/4885CA9 4538/4885 |
| US-20140275572-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | CYP21A2, PGR, CYP17A1 | CA12 2368/4885CA1 3445/4885CA9 3197/4885 |
| US-20160168188-A1 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF | CYP21A2, PGR, CYP17A1 | CA12 2368/4885CA1 3445/4885CA9 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.